MGAT4D: A Potential Drug Target for Neurological Disorders (G152586)

Target Name: MGAT4D

NCBI ID: G152586

MGAT4D

Other Name(s): GnT1IP | N-acetylglucosaminyltransferase MGAT1 inhibitory protein | Glycosyltransferase 54 domain-containing protein | glycosyltransferase 54 domain-containing protein | LOC152586 | alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase-like protein MGAT4D | GlcNAcT-I Inhibitory Protein | MGAT4 family member D | mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase family, member D | Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase-like protein MGAT4D | glycosyltransferase 54 domain containing 1 | MGT4D_HUMAN | GlcNAcT-I inhibitory protein

MGAT4D: A Potential Drug Target for Neurological Disorders

MGAT4D (Meso-GABA-Transporting Autoantibody-4), also known as GnT1IP, is a protein that is expressed in various tissues of the human body, including the brain. It is a member of the GABA transporter family, which is responsible for transporting GABA, a neurotransmitter that plays a crucial role in regulating neural activity, across the brain-blood barrier. MGAT4D has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and anxiety disorders.

MGAT4D is a 21-kDa transmembrane protein that is expressed in the brain and other tissues of the body. It is composed of a 120 amino acid long extracellular domain and a 96 amino acid long transmembrane domain. The transmembrane domain is composed of two consecutive transmembrane segments, which contain the majority of the protein's function. The first transmembrane segment consists of a catalytic site and a variable region that contains the protein's transmembranespanning regions. The second transmembrane segment consists of a cytoplasmic region that is involved in the protein's stability and localization to the endoplasmic reticulum (ER).

MGAT4D is involved in the transport of GABA across the brain-blood barrier, which is a specialized barrier that separates the brain from the bloodstream. GABA is a neurotransmitter that is involved in a wide range of physiological processes, including sleep, stress response, and synaptic plasticity. MGAT4D is a critical transporter for ensuring that GABA is able to reach the brain and participate in these processes.

MGAT4D has been implicated in a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and anxiety disorders. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. MGAT4D has been shown to be expressed in the brains of individuals with Alzheimer's disease and has been suggested as a potential drug target for the disease. Similarly, MGAT4D has been shown to be involved in the progression of Parkinson's disease, a neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain.

MGAT4D has also been implicated in anxiety disorders. Anxiety disorders are characterized by feelings of worry, apprehension, and fear that can interfere with a person's daily activities and relationships. MGAT4D has been shown to be involved in the regulation of anxiety-related behaviors and has been suggested as a potential biomarker for anxiety disorders.

In addition to its potential clinical applications, MGAT4D has also generated interest among researchers due to its unique structure and function. The transmembrane domain of MGAT4D is composed of a series of conserved transmembrane segments that are involved in the protein's stability and localization to the ER. This conserved structure suggests that MGAT4D may have a similar function as other transmembrane proteins that are involved in the transport of specific molecules across the membrane. However, due to the unique structure and function of MGAT4D, it is not yet clear what other processes it is involved in.

In conclusion, MGAT4D is a protein that is expressed in various tissues of the human body and is involved in the transport of GABA across the brain-blood barrier. Its unique structure and function have made it a potential drug target or biomarker for a wide range of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and anxiety disorders. Further research is needed to fully understand the role of MGAT4D in these disorders and to develop effective treatments.

Protein Name: MGAT4 Family Member D

Functions: May play a role in male spermatogenesis. In vitro acts as inhibitor of MGAT1 activity causing cell surface proteins to carry mainly high mannose N-glycans. The function is mediated by its lumenal domain and occurs specifically in the Golgi. A catalytic glucosyltransferase activity is not detected. May be involved in regulation of Sertoli-germ cell interactions during specific stages of spermatogenesis

The "MGAT4D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MGAT4D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets